The Irish Haemophilia Society is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community.

VGA039 is a subcutaneous monoclonal antibody therapy designed to target Protein S as a means of restoring proper blood clotting in people with all types of VWD.

Novo’s BLA submission was based on results of the FRONTIER clinical study program, a series of clinical trials designed to establish the efficacy and safety of denecimig as a prophylactic therapy to prevent or reduce the frequency of bleeding episodes in people with hemophilia A, with or without inhibitors.

The study authors looked for potential trends in health equity, diversity, and inclusion among Black/African Americans, indigenous people of color (e.g. Native Americans and Asian Pacific Islanders), and Hispanic/Latino people with bleeding disorders.

The Resource Roundup is a monthly communication designed to connect the bleeding disorders community with timely, practical, and readily accessible resources.

Get to know the inspiring runners who are challenging themselves by running the TCS New York City Marathon, and finding inspiration in the bleeding disorders community along the way.

WHO adds emicizumab and recombinant clotting factors to its Essential Medicines List, a major win for global bleeding disorders care and access.

FDA expands VONVENDI approval to include prophylaxis for adults with von Willebrand disease and pediatric on-demand use, advancing care across all VWD types.

NBDF advocates for bleeding disorders care and coverage—BDC 2025 highlights, federal policy updates, Medicaid privacy, insurance reforms, and state actions.

A New Class of Cellular Medicines: The First Engineered B Cell Medicine to Enter Clinical Trials for Hemophilia B